Cardiac Magnetic Resonance Imaging in Heart Failure

Selen BAYRAKTAROĞLUa , Erencan KARAKOÇa
aEge University Faculty of Medicine, Department of Radiology, İzmir, Türkiye

Bayraktaroğlu S, Karakoç E. Cardiac magnetic resonance imaging in heart failure. In: Bayraktaroğlu S, ed. Advances in Cardiovascular System Imaging. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.47-53.

ABSTRACT
Cardiac magnetic resonance imaging (MRI), a rapidly growing imaging modality in recent years, is a non-invasive, ionizing radiation-free technique that assists in evaluating cardiac function, morphology, and tissue characteristics. While the diagnosis of heart failure is generally based on echocardiographic findings, clinical signs, and laboratory findings, cardiac MRI plays an important role in the early diagnosis of heart failure, differential diagnosis of underlying causes, and predicting the prognosis of patients with heart failure. In this review, we aim to evaluate the current applications and the future of cardiac MRI in the evaluation of heart failure.

Keywords: Magnetic resonance imaging; heart failure; cardiomyopathies; cardiac imaging techniques

Referanslar

  1. Colucci WS, Barlaug BA (author), Gottlieb SS (section editor), Dardas TF (deputy editor). Heart failure: Clinical manifestations and diagnosis in adults. In UptoDate. (cited: May 8, 2024).Wolters Kluwer.
  2. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. [Crossref]
  3. Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149(8):e347-e913. [Crossref]
  4. Çavuşoğlu Y, Altay H, Aras D, Çelik A, Ertaş Sinan F, Kılıçaslan B, et al. Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs. Balkan Med J 2022;39:282-9. [Crossref]
  5. TÜİK [İnternet] [Erişim Tarihi: 9 Mayıs 2024]. Erişim linki: [Link]
  6. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361(9355):374-9. [Crossref]
  7. Roifman I, Hammer M, Sparkes J, Dall'Armellina E, Kwong RY, Wright G. Utilization and impact of cardiovascular magnetic resonance on patient management in heart failure: insights from the SCMR Registry. J Cardiovasc Magn Reson. 2022;24(1):65. [Crossref]
  8. Peterzan MA, Rider OJ, Anderson LJ. The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. Card Fail Rev. 2016;2(2):115-22. [Crossref]
  9. Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, et al. Gadoversetamide Myocardial Infarction Imaging Investigators. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation. 2008;117(5):629-37. [Crossref]
  10. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270-6. [Crossref]
  11. McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108(1):54-9. [Crossref]
  12. Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. JACC Cardiovasc Imaging. 2018;11(9):1274-84. [Crossref]
  13. Puntmann VO, Carr-White G, Jabbour A, Yu CY, Gebker R, Kelle S, et al; International T1 Multicentre CMR Outcome Study. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. JACC Cardiovasc Imaging. 2016;9(1):40-50. [Crossref]
  14. Aljizeeri A, Sulaiman A, Alhulaimi N, Alsaileek A, Al-Mallah MH. Cardiac magnetic resonance imaging in heart failure: where the alphabet begins! Heart Fail Rev. 2017;22(4):385-99. [Crossref]
  15. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-626. [Crossref]
  16. Weir-McCall JR, Yeap PM, Papagiorcopulo C, Fitzgerald K, Gandy SJ, Lambert M, et al. Left Ventricular Non-compaction: Anatomical Phenotype or Distinct Cardiomyopathy? J Am Coll Cardiol. 2016;68(20):2157-65. [Crossref]
  17. Demir E, Bayraktaroğlu S, Çinkooğlu A, Candemir A, Candemir YB, Öztürk RO, et al. Characteristics and long-term survival of patients with left ventricular non-compaction cardiomyopathy. ESC Heart Fail. 2022;9(6):4219-29. [Crossref]
  18. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis--diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015;12(11):670-80. [Crossref]
  19. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018;72(24):3158-76. [Crossref]
  20. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al. Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial. J Am Coll Cardiol. 2016;67(15):1800-11. [Crossref]
  21. Liu C, Ferrari VA, Han Y. Cardiovascular Magnetic Resonance Imaging and Heart Failure. Curr Cardiol Rep. 2021;23(4):35. [Crossref]
  22. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):133-42. [Crossref]
  23. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020;13(1 Pt 1):69-80. [Crossref]
  24. Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: A systematic review and meta-analysis. ESC Heart Fail. 2019;6:1041-51. [Crossref]
  25. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570-9. [Crossref]
  26. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244-51. [Crossref]
  27. Bayraktaroglu S, Karadas N, Onen S, Karapinar DY, Aydinok Y. Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study. Ann Hematol. 2022;101(3):521-9. [Crossref]
  28. Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac Sarcoidosis. J Am Coll Cardiol. 2016;68(4):411-21. [Crossref]
  29. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014;7(6):1109-15. [Crossref]
  30. Myerson SG. CMR in evaluating valvular heart disease: diagnosis, severity, and outcomes. JACC Cardiovasc Imaging. 2021;14(10):2020-3.2 [Crossref]
  31. Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, et al. Mid-wall fibrosis is an independent predictor of mortality in patients with aortic stenosis (abstract). J Am Coll Cardiol. 2011;58(12):1271-9. [Crossref]
  32. Musa TA, Treibel TA, Vassiliou VS, Captur G, Singh A, Chin C, et al. Myocardial Scar and Mortality in Severe Aortic Stenosis. Circulation. 2018;138(18):1935-47. [Crossref]
  33. Zarifa A, Albittar A, Kim PY, Hassan S, Palaskas N, Iliescu C, et al. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy. Curr Opin Cardiol. 2019;34(4):441-50. [Crossref]
  34. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36):3599-726. [Crossref]